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Abstract  The stomach is an infrequent site of breast cancer metastasis. It may prove very difficult to distinguish a breast 
cancer metastasis to the stomach from a primary gastric cancer on the basis of clinical, endoscopic, radiological and 
histological features. We present a case of a 57-year-old woman of gastric metastasis from breast cancer by 
immunohistochemistry 6 years after mastectomy. Since no other lesions were observed in the image examination, she 
underwent laparoscopic gastrectomy and endocrine therapy. The patient remains well after 6 years from gastrectomy. 
Complete histopathological and immunohistochemical analysis of the gastric biopsies and comparison with the original 
breast cancer pathology is important. 
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Introduction 
Breast cancer has become the most common 
malignancy in Japanese women as well as women in 
Western countries. Breast cancer metastasis to the 
gastrointestinal (GI) tract is rare, with typical 
metastatic sites being the lung, bones, liver, and 
brain[1]. Breast cancer cases with lobular pathology 
show a higher tendency of metastases to the stomach, 
typically presenting as linitis plastica[2].  It is 
important to distinguish between breast cancer 
metastasis to the stomach, and primary gastric cancer 
since the treatment plans for these two malignancies 
are different. Here, we report a case of invasive 
ductal carcinoma of the breast involving the stomach, 
with the breast confirmed to be the primary site.  
Case report 
A 51-year-old woman underwent mastectomy with 
axillary lymph node dissection for invasive ductal 
carcinoma of the left breast in November 2004 (Fig. 
1). Pathological examination revealed lymph node 
involvement, positive estrogen receptor (ER) and 
progesterone receptor (PgR), and negative human 
epithelial growth factor  receptor type 2 (HER2) 
pro tein .  She underwent  adjuvant  chemotherapy 
(epirubicin and cyclophosphamide,  fol lowed by 
docetaxel) and endocrine therapy ( tamoxifen 20 
mg/day switched to letrozole 2.5 mg/day).  Two years 
a f t e r  m a s t e c t o m y ,  s h e  u n d e r w e n t  b r e a s t 
reconstruction surgery.  Six years a fter  surgery, 
e l e v a t e d  t u mo r  ma r k e r  l e v e l s  we r e  r e c o r d e d  
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(CEA, 10.9 ng/mL; CA15-3, 53.0 U/mL); Positron 
Emission Tomography revealed accumulation in the 
stomach (Fig. 2). Gastroscopy findings showed 
revealed an IIc like lesion in the mid greater 
curvature of the stomach (Fig. 3).  Biopsy specimen 
showed atypical cells with slightly enlarged nuclei in 
the lamina propria. Further immunohistochemical 
(IHC) findings were positive for ER, negative for 
PgR, positive for gross cystic disease fluid 
protein-15 (GCDFP-15), and positive for E-cadherin 
(Fig. 4). These findings suggested that the gastric 
lesion was metastatic from the breast cancer. The 
patient was treated with capecitabine (1250 mg/m2 
bid, days 1–14, q3w) and exemastane (25 mg/day); 
however the gastric metastasis progressed, with a 
time to progression of 12 months.  As no other 
metastatic lesions were observed on imaging 
examination, laparoscopic subtotal gastrectomy was 
performed in March 2012. Following gastrectomy, 
hormonal therapy with fulvestrant (500 mg/body) 
was administered, and the patient has remained well 
6 years following gastrectomy.   
 
    
 
 
 
 
 
 
 
 
 
 
Discussion 
The metastasis of primary breast cancer to the GI 
tract is relatively rare; however there have been case 
reports documenting recurrences in the stomach and 
duodenum several years following the initial 
treatment for primary breast cancer[3]. Lobular 
carcinomas show a higher propensity to metastasize 
to the GI tract, with the incidence rate reported to be 
2% to 18%[2,5] of all breast cancer cases.  Although 
lobular carcinoma is the most common histological 
type of gastric metastasis, ductal carcinoma can also 
metastasize to the stomach[6]. Although the GI tract 
is a rare metastatic site of extra -abdominal carcinoma, 
breast cancer is reported to be the second most 
common primary site responsible, following lung 
cancer[7,8,9]. The clinical presentation of metastatic 
breast carcinoma to the GI tract is often the same as 
that of primary GI malignancies. Regarding clinical 
symptoms of gastric metastasis, Cormier et al.[2] 
have reported that 29 of the 31 patients with gastric 
metastasis showed digestive symptoms, weight loss, 
nausea,  epigastr ic  pain,  ear ly sat iety,  and melena ,  
 
 
 
Fig. 1  Histological findings of the primary site of breast cancer. 
Left; ×40, Right; ×200 (H.E stain) 
Fig. 2  PET examination showed 
accumulation in the stomach fornix. 
 
Fig.3  The gastroscopic findings showed 
an IIc-like lesion in the mid greater 
curvature side of the stomach. 
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while only 2 patients were symptom-frees. In the 
present case, no symptoms were present, and only 
elevated tumor markers were identified. Diffuse 
infiltration of the stomach is a characteristic of 
metastasis from invasive lobular carcinoma, and 
linitis plastica with diffuse infiltra tion of the 
submucosa and lamina propria is a common imaging 
finding[8]. In invasive ductal carcinoma, endoscopic 
features are variable, and it is reported to represent 
gastric metastasis with more discrete nodules[2].  
Accurately distinguishing gastric metastasis from 
either primary gastric cancer or gastritis -based 
endoscopic features alone may be difficult in 
invasive lobular and ductal carcinomas, due to the 
variable endoscopic appearance of the gastric 
metastasis of primary breast cancer[6,8].    
Therefore, detailed IHC staining is necessary to 
differentiate metastatic carcinoma from primary 
gastric cancer[10]. IHC staining for ER and PgR 
appears to be useful for distinguishing metastasis 
from breast cancer; however, i t is noteworthy that 
ER- and PgR-positivity has been reported in 32% and 
12% of the primary gastric cancer cases, 
respectively[10,11]. GCDFP-15 staining is useful to 
diagnose whether a cases is a metastatic tumor from 
breast cancer or primary gastric cancer[12], because 
GCDFP-15 is a sensitive (45%–76%) and specific 
(91.8%–100%) marker. However, GCDFP-15 is 
expressed in apocrine and salivary glands.  Thus, ER 
and GCDFP-15 staining is useful for diagnosing 
metas t a t i c  ca r c ino ma  f r o m t he  b r eas t ,  and  i t  i s  
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important to compare results of IHC staining between 
primary and metastatic sites.  
Taal et al.[6] have reported that gastric metastasis 
alone was present in 5.8% of the cases of metastatic 
breast cancer; and that majority of the cases of 
gastric metastasis were associated with the 
involvement of another organ, including the bones, 
liver, or lung. The treatment strategy for gastric 
metastasis from breast cancer comprises systemic 
therapy (chemotherapy, hormonal therapy, or both). 
Surgical resection of the stomach has a limited role 
in treatment and does not affect the survival 
outcomes of patients presenting with gastric 
metastasis[7,13]. However, surgery may be 
performed in palliative care for symptom relief and 
supportive care, and decision-making for surgical 
planning should be based on clinical presentation and 
symptoms. In the present case, oral chemotherapy 
and hormone therapy, gastrectomy was performed as 
there was no other metastatic lesion.  
Patients with breast cancer show superior survival 
outcomes compared to those with other types of 
cancers, increasing the possibility of a second 
primary cancer arising during the clinical course. 
However, metastasis of primary breast carcinoma 
must also be considered. Gastric metastasis from 
breast cancer is rarely observed in metastatic breast 
carcinoma. However, it is important to distinguish 
gastric metastasis from breast cancer metastasis to 
determine the initial treatment of breast cancer as a 
systemic disease.  
Fig. 4  The biopsy specimen revealed the atypical cells in the lamina propria.  
IHC examinations showed positive ER, GCDFP-15 and E-cadherin staining. 
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